Oral Versus IV Iron, Populations That Warrant Upfront Escalation, the Implementation Gap, and Always Finding the Underlying Cause

Freed outlines which patients should proceed directly to IV iron without a trial of oral therapy and why oral iron follow-up is inadequately practiced in the United States.

The decision between oral and IV iron is not a single binary choice but a clinical stratification that begins before the prescription is written. Certain populations can be identified prospectively as unlikely to derive meaningful benefit from oral iron and should proceed directly to IV iron: patients with gastrointestinal conditions that impair absorption, including gastric bypass surgery, inflammatory bowel disease, and celiac disease; patients whose rate of iron loss exceeds the capacity of oral absorption to keep pace, most commonly women with heavy menstrual bleeding that has not yet been adequately addressed and patients with chronic gastrointestinal blood loss; patients with advanced chronic kidney disease, in whom elevated hepcidin levels — accumulated due to impaired renal clearance — suppress intestinal iron absorption and render oral supplementation largely ineffective, a problem that begins well before dialysis initiation; patients with congestive heart failure, for whom a substantial evidence base supports IV iron as the preferred route; and patients with chronic inflammatory diseases broadly, in whom inflammation-driven hepcidin upregulation similarly suppresses oral iron absorption. For patients who do not fall into these categories, an appropriate trial of oral iron is reasonable, but it must be followed: the hemoglobin should be rechecked at 4 to 6 weeks, and failure to improve is the indication for conversion to IV iron. Multiple studies have documented that this follow-up is not occurring in the majority of cases in the United States, meaning patients who fail oral iron are frequently not identified as having done so and are not escalated.

The forward-looking challenge in iron deficiency is not primarily scientific but operational. The tools and treatments needed to dramatically reduce the burden of iron deficiency in the United States already exist. The priority question is how to close the gap between what is known and what is practiced — fixing reference ranges at the health system level through institutional advocacy; creating rapid-access pathways for IV iron in appropriate patients; ensuring that women of reproductive age are screened and treated for iron deficiency before they become pregnant, so that clinicians are not encountering severely iron-deficient patients at the first prenatal visit. On the horizon, new IV iron formulations are expected to enter the market with the potential to reduce infusion costs and expand the number of agents capable of delivering full replacement doses in a single short session with a favorable reaction profile. These are meaningful incremental advances, but they are secondary to the implementation work already warranted by the agents available today.

In this final segment of the video discussion on iron deficiency anemia, Jason Freed, MD, closes with what he describes as the principle most important to carry into practice: iron deficiency is never a complete diagnosis. Identifying that a patient is iron deficient is the beginning of the clinical workup, not the end of it, and the underlying cause must always be sought and addressed — repletion without source control produces temporary benefit and inevitable recurrence. In premenopausal women, structured assessment of menstrual blood loss — including questions about the number of saturated pads or tampons used per day, nocturnal changes, missed work or school, and clot size — reveals heavy menstrual bleeding far more frequently than a single unstructured inquiry. In men, iron deficiency should not be explained away by secondary factors such as proton pump inhibitor use; 90% of men with unexplained iron deficiency will have a gastrointestinal cause identified on upper endoscopy and colonoscopy, and the workup should not be deferred. Freed frames this emphasis on source identification not as an additional burden on the clinician but as the necessary condition for any treatment intervention to produce durable benefit — a principle that applies as much to the individual patient as it does to the field's broader effort to reduce the health burden of a condition that is, by every available measure, being massively undertreated.